# Veterinary Molecular Diagnostics Market Size, Share, and Trends - Global Forecast to 2036 | Point-of-Care PCR, Sequencing, and Genomic Testing Drive 9.2% CAGR Toward USD 2.13 Billion

- Published: 2026-11-16
- Author: [BiotechNews.io](https://biotechnews.io/author/biotechnews-io.md)
- Topics: [News](https://biotechnews.io/news.md)
- Source: https://biotechnews.io/news/veterinary-molecular-diagnostics-market-size-share-and-trends-global-forecast-to-2036-poin/
- Publication: Biotech News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://biotechnews.io/editorial-policy/

*Prioritize point-of-care PCR, sequencing, genetics and software; drive returns through multiplex panels, automation, partnerships and Asia-Pacific expansion.*

Dublin, Nov. 16, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- <a href="https://www.researchandmarkets.com/reports/6290686/veterinary-molecular-diagnostics-market-size?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=9tw2q9&amp;utm_campaign=2404611+-+Veterinary+Molecular+Diagnostics+Market+Size%2c+Share%2c+and+Trends+-+Global+Forecast+to+2036+%7c+Point-of-Care+PCR%2c+Sequencing%2c+and+Genomic+Testing+Drive+9.2%25+CAGR+Toward+USD+2.13+Billion&amp;utm_exec=clshmsai" rel="nofollow">"Veterinary Molecular Diagnostics Market Size, Share, and Trends - Forecast to 2036"</a> has been added to **ResearchAndMarkets.com's** offering.

The global veterinary molecular diagnostics market was valued at USD 812.6 million in 2025 and is estimated to reach USD 886.4 million in 2026. The market is projected to grow to USD 2.13 billion by 2036, representing a CAGR of 9.2% during 2026-2036. Growth is being driven by infectious disease outbreaks, expanding animal health surveillance, rising companion animal expenditure, livestock genomic testing, and adoption of point-of-care molecular diagnostics.

The report assesses veterinary molecular diagnostics kits, reagents, instruments, and software used for disease diagnosis, surveillance, pathogen characterization, and animal genetic testing. Covered technologies include real-time, digital, and conventional PCR; multiplex syndromic panels; extraction kits and automated systems; thermal cyclers; point-of-care molecular analyzers; DNA sequencing; genotyping microarrays; and laboratory and data analysis software. Immunoassays, rapid antigen and antibody tests, clinical chemistry, hematology, imaging, food safety testing, environmental DNA monitoring, and human molecular diagnostics are excluded.

**Market Drivers and Opportunities**

Transboundary and zoonotic disease outbreaks remain central to market expansion. According to the World Organisation for Animal Health, African swine fever was reported by 76 countries and territories between January 2022 and June 2026. The period included 14,951 outbreaks in domestic pigs, 2.74 million animals lost, and 34,388 outbreaks in wild boar. Finland subsequently recorded its first wild boar case in July 2026.

Bluetongue surveillance is also increasing testing demand. By August 7, 2026, the U.K. Department for Environment, Food & Rural Affairs had confirmed 270 bluetongue virus serotype 3 cases on farms in England and Wales, following 348 cases in Great Britain during 2025-2026. In the U.S., H5N1 avian influenza detection in dairy cattle has supported continued testing under the National Milk Testing Strategy and the Federal Order requiring tests before interstate movement of lactating dairy cattle.

Companion animal diagnostics provide another significant growth engine. Higher pet ownership, increased healthcare spending, and broader PCR panels for respiratory, gastrointestinal, and vector-borne diseases are supporting recurring laboratory demand. IDEXX Laboratories reported second-quarter 2026 revenue of USD 1.21 billion, up 10%, while Companion Animal Group Diagnostics recurring revenue increased 11%.

Key opportunities include point-of-care PCR and isothermal systems capable of delivering results in veterinary clinics or on farms. Whole-genome sequencing is gaining importance for strain identification, outbreak tracing, variant monitoring, and antimicrobial resistance analysis. One Health surveillance programs, expanding veterinary laboratory infrastructure in China, India, Brazil, and Southeast Asia, multiplex panels, and integration with practice management and surveillance platforms are expected to create additional commercial opportunities.

Market expansion is constrained by higher molecular testing costs, specialized equipment requirements, trained personnel shortages, and limited veterinary laboratory capacity in parts of Africa, Asia, and Latin America. National approval and validation requirements can lengthen commercialization timelines, while outbreak-related fluctuations complicate capacity and inventory planning.

**Segment Analysis**

Kits & reagents are expected to hold the largest product share in 2026 because PCR assays, extraction products, and sequencing reagents are consumed with each test. Software is projected to record the highest CAGR as laboratories connect diagnostic results with information systems, practice management tools, bioinformatics platforms, and government surveillance networks. Instrument demand will benefit from laboratory automation and point-of-care adoption.

PCR is expected to remain the leading technology in 2026 due to its established role in confirming viral and bacterial pathogens and supporting national surveillance programs for African swine fever, avian influenza, and bluetongue. DNA sequencing is forecast to grow the fastest as costs decline and whole-genome sequencing becomes more widely used for pathogen typing, outbreak investigation, resistance detection, and animal genotyping. Microarrays will continue to support livestock genomic selection.

Infectious diseases will account for the largest application share, reflecting sustained demand for livestock surveillance and routine companion animal testing. Genetics is projected to achieve the highest CAGR, supported by genomic selection in cattle, swine, and poultry, as well as inherited disease, trait, parentage, and identity testing for companion animals and livestock.

Companion animals are expected to hold the largest market share in 2026, supported by strong veterinary spending and frequent use of reference laboratory panels. Livestock diagnostics are forecast to grow faster as national surveillance, pre-movement testing, and breeder adoption of genomic tools increase. Cattle testing will be supported by H5N1 surveillance in dairy herds, bluetongue monitoring, and genomic selection programs.

Veterinary reference & diagnostic laboratories will remain the largest end-user segment because advanced molecular testing is concentrated in facilities with specialized instruments, automation, and technical expertise. Veterinary hospitals & clinics are expected to grow the fastest as point-of-care platforms enable testing during consultations and large veterinary groups expand in-house diagnostic capabilities.

**Regional Outlook**

North America is expected to lead the veterinary molecular diagnostics market in 2026. Regional growth is supported by high companion animal healthcare expenditure, established reference laboratory networks, major suppliers including IDEXX, Antech Diagnostics, Zoetis, Neogen, and Thermo Fisher Scientific, and extensive livestock disease surveillance. The U.S. also represents a major market for livestock genomic testing.

Asia-Pacific is projected to register the highest CAGR, driven by large swine and poultry populations, African swine fever and avian influenza surveillance, laboratory investment, commercial farm expansion, and rising pet care spending. China is expected to generate substantial PCR demand through African swine fever control programs and consolidation of livestock production.

Europe will maintain a significant share due to African swine fever, bluetongue, and avian influenza outbreaks, strong national laboratory systems, and regional diagnostic specialists. Latin America offers opportunities linked to the livestock industries of Brazil, Argentina, and Mexico. The Middle East & Africa will benefit from gradual investment in veterinary services, laboratory capacity, and disease control programs.

**Competitive Landscape**

The moderately consolidated market includes IDEXX Laboratories, Antech Diagnostics, Zoetis, Thermo Fisher Scientific, QIAGEN, Bio-Rad Laboratories, Neogen, Indical Bioscience, and Innovative Diagnostics. Competition focuses on assay menu breadth, regulatory validation, sensitivity and specificity, throughput, automation, turnaround time, point-of-care capability, laboratory networks, and relationships with veterinary authorities.

Leading companies are expanding multiplex assay portfolios, investing in sequencing and automation, and connecting diagnostics with software platforms. Strategic developments include Neogen's March 2026 agreement to sell its GeneSeek genomics business, including the Igenity and GGP portfolios, to Zoetis, as well as Mars' combination of Heska with Antech Diagnostics.

**Report Value**

-   Provides veterinary molecular diagnostics market size estimates and forecasts through 2036.
-   Evaluates the effects of African swine fever, H5N1 avian influenza, bluetongue, and companion animal healthcare trends.
-   Identifies growth opportunities across products, technologies, applications, animal types, end users, and regions.
-   Assesses point-of-care PCR, multiplex testing, whole-genome sequencing, and animal genomics.
-   Reviews market barriers including cost, laboratory capacity, regulatory requirements, and demand volatility.
-   Benchmarks leading companies, diagnostic platforms, assay portfolios, laboratory networks, and strategic transactions.
-   Supports product development, investment, partnership, and market entry decisions.

**Key Topics Covered:**  
  
**1\. Introduction**  
1.1. Market Definition  
1.2. Market Ecosystem  
1.3. Currency and Limitations  
1.3.1. Currency  
1.3.2. Limitations  
1.4. Key Stakeholders  
  
**2\. Research Methodology**  
2.1. Research Approach  
2.2. Data Collection & Validation Process  
2.2.1. Secondary Research  
2.2.2. Primary Research & Validation  
2.2.2.1. Primary Interviews with Industry Experts  
2.2.2.2. Country-/Region-Level Analysis  
2.3. Market Estimation  
2.3.1. Bottom-Up Approach  
2.3.2. Top-Down Approach  
2.3.3. Forecast Methodology  
2.4. Data Triangulation  
2.5. Assumptions  
  
**3\. Executive Summary**  
  
**4\. Market Overview**  
4.1. Introduction  
4.2. Market Dynamics  
4.2.1. Drivers  
4.2.1.1. Rising Incidence of Transboundary and Zoonotic Animal Diseases  
4.2.1.2. Growing Companion Animal Population and Pet Healthcare Spending  
4.2.1.3. Expansion of Reference Laboratory Molecular Testing Panels  
4.2.1.4. Increasing Adoption of Genomic Testing in Livestock  
4.2.2. Restraints  
4.2.2.1. High Cost of Molecular Testing  
4.2.2.2. Limited Laboratory Infrastructure in Developing Countries  
4.2.3. Opportunities  
4.2.3.1. Point-of-Care Molecular Testing in Veterinary Clinics  
4.2.3.2. Sequencing for Pathogen Characterization and Genomic Surveillance  
4.2.3.3. One Health and Zoonotic Disease Surveillance Programs  
4.2.3.4. Expansion of Veterinary Laboratory Infrastructure in Emerging Economies  
4.2.4. Challenges  
4.2.4.1. Regulatory Approval and Validation of Veterinary Assays  
4.2.4.2. Interpretation of PCR Results and Outbreak-Driven Demand Volatility  
4.2.5. Trends  
4.2.5.1. Shift Toward Multiplex Syndromic Panels  
4.2.5.2. Consolidation and Integration of Diagnostics and Genetics  
4.2.5.3. Integration of Molecular Diagnostics with Data and Software Platforms  
4.3. Technology Landscape  
4.3.1. Real-Time and Digital PCR  
4.3.2. Multiplex Syndromic Panels  
4.3.3. Point-of-Care and Isothermal Molecular Platforms  
4.3.4. Next-Generation Sequencing and Whole-Genome Sequencing  
4.3.5. Genotyping Microarrays  
4.3.6. Laboratory Automation and Informatics  
4.4. Molecular vs. Immunoassay-Based Veterinary Diagnostics: Comparative Analysis  
4.5. Animal Disease Landscape  
4.5.1. African Swine Fever  
4.5.2. Highly Pathogenic Avian Influenza (Including H5N1 in Dairy Cattle)  
4.5.3. Bluetongue and Other Vector-Borne Diseases  
4.5.4. Foot-and-Mouth Disease and Other Transboundary Diseases  
4.5.5. Companion Animal Infectious Diseases  
4.6. Value Chain Analysis  
4.6.1. Assay and Instrument Development  
4.6.2. Manufacturing and Validation  
4.6.3. Distribution  
4.6.4. Laboratory and Point-of-Care Testing  
4.6.5. Data, Reporting, and Surveillance  
4.7. Regulatory Landscape  
4.7.1. WOAH Manual of Diagnostic Tests and Vaccines for Terrestrial Animals  
4.7.2. North America (USDA CVB, NAHLN)  
4.7.3. Europe (EU Animal Health Law, National Reference Laboratories)  
4.7.4. Asia-Pacific  
4.8. Porter's Five Forces Analysis  
4.9. Pricing and Cost-per-Test Analysis  
  
**5\. Veterinary Molecular Diagnostics Market, by Product**  
5.1. Introduction  
5.2. Kits & Reagents  
5.2.1. PCR Assay Kits  
5.2.2. Nucleic Acid Extraction Kits  
5.2.3. Sequencing Kits & Reagents  
5.2.4. Other Reagents  
5.3. Instruments  
5.3.1. PCR Systems  
5.3.2. Sequencing Systems  
5.3.3. Nucleic Acid Extraction Systems  
5.3.4. Point-of-Care Molecular Analyzers  
5.4. Software  
  
**6\. Veterinary Molecular Diagnostics Market, by Technology**  
6.1. Introduction  
6.2. Polymerase Chain Reaction (PCR)  
6.2.1. Real-Time PCR  
6.2.2. Digital PCR  
6.2.3. Conventional PCR  
6.3. DNA Sequencing  
6.3.1. Next-Generation Sequencing  
6.3.2. Sanger Sequencing  
6.4. Microarray  
6.5. Other Technologies  
  
**7\. Veterinary Molecular Diagnostics Market, by Application**  
7.1. Introduction  
7.2. Infectious Diseases  
7.2.1. Viral Diseases  
7.2.2. Bacterial Diseases  
7.2.3. Parasitic Diseases  
7.2.4. Fungal Diseases  
7.3. Genetics  
7.3.1. Genetic Disease Testing  
7.3.2. Genomic Selection & Trait Testing  
7.3.3. Parentage & Identity Testing  
7.4. Metabolic Diseases  
7.5. Other Applications  
  
**8\. Veterinary Molecular Diagnostics Market, by Animal Type**  
8.1. Introduction  
8.2. Companion Animals  
8.2.1. Dogs  
8.2.2. Cats  
8.2.3. Horses  
8.2.4. Other Companion Animals  
8.3. Livestock Animals  
8.3.1. Cattle  
8.3.2. Swine  
8.3.3. Poultry  
8.3.4. Small Ruminants  
8.3.5. Other Livestock Animals  
  
**9\. Veterinary Molecular Diagnostics Market, by End User**  
9.1. Introduction  
9.2. Veterinary Reference & Diagnostic Laboratories  
9.3. Veterinary Hospitals & Clinics  
9.4. Research Institutes  
  
**10\. Veterinary Molecular Diagnostics Market, by Geography**  
10.1. Introduction  
10.2. North America  
10.2.1. U.S.  
10.2.2. Canada  
10.3. Europe  
10.3.1. Germany  
10.3.2. France  
10.3.3. U.K.  
10.3.4. Italy  
10.3.5. Spain  
10.3.6. Netherlands  
10.3.7. Poland  
10.3.8. Rest of Europe  
10.4. Asia-Pacific  
10.4.1. China  
10.4.2. Japan  
10.4.3. India  
10.4.4. South Korea  
10.4.5. Australia  
10.4.6. Vietnam  
10.4.7. Rest of Asia-Pacific  
10.5. Latin America  
10.5.1. Brazil  
10.5.2. Mexico  
10.5.3. Argentina  
10.5.4. Rest of Latin America  
10.6. Middle East & Africa  
10.6.1. Saudi Arabia  
10.6.2. South Africa  
10.6.3. Rest of Middle East & Africa  
  
**11\. Competitive Landscape**  
11.1. Overview  
11.2. Key Growth Strategies  
11.3. Competitive Benchmarking  
11.4. Competitive Dashboard  
11.4.1. Market Leaders  
11.4.2. Market Differentiators  
11.4.3. Vanguards  
11.4.4. Emerging Players  
11.5. Market Share/Rank Analysis, by Key Player, 2025  
  
**12\. Company Profiles**  
Business Overview, Financial Overview, Veterinary Molecular Diagnostics Portfolio, Product Portfolio, Strategic Developments, SWOT Analysis  
12.1. IDEXX Laboratories, Inc.  
12.2. Antech Diagnostics, Inc. (Mars, Incorporated)  
12.3. Zoetis Inc.  
12.4. Thermo Fisher Scientific Inc.  
12.5. QIAGEN N.V.  
12.6. Bio-Rad Laboratories, Inc.  
12.7. Neogen Corporation  
12.8. Indical Bioscience GmbH  
12.9. Innovative Diagnostics SAS  
  
**13\. Appendix**  
13.1. Related Reports  
13.2. Customization Options  
  
**List of Tables \[477\]**  
**List of Figures \[42\]**  
  
For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6290686/veterinary-molecular-diagnostics-market-size?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=9tw2q9&amp;utm_campaign=2404611+-+Veterinary+Molecular+Diagnostics+Market+Size%2c+Share%2c+and+Trends+-+Global+Forecast+to+2036+%7c+Point-of-Care+PCR%2c+Sequencing%2c+and+Genomic+Testing+Drive+9.2%25+CAGR+Toward+USD+2.13+Billion&amp;utm_exec=clshmsai" rel="nofollow">https://www.researchandmarkets.com/r/v59vox</a>

**About ResearchAndMarkets.com**  
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900 

  
![](https://ml.globenewswire.com/media/ZGJhMDEzMjctM2U2Ny00ZGU3LTk4YWQtNzQzODZlYjNmYTIxLTEwMjY3MzctMjAyNi0xMS0xNi1lbg==/tiny/Research-and-Markets.png)

## Related

- [Global Human Liver Model Market Report 2026: Size, Share, Trends, and Forecast to 2030 | 3D Models and Organ-on-a-Chip Propel 15.03% CAGR and US$3.81 Billion Opportunity](https://biotechnews.io/news/global-human-liver-model-market-report-2026-size-share-trends-and-forecast-to-2030-3d-mode.md)
- [Mice Model - Global Strategic Business Report 2026: Capitalize on a $3.4 Billion Market by 2032 as Charles River, LabCorp, Taconic Biosciences and The Jackson Laboratory Accelerate CRISPR](https://biotechnews.io/news/mice-model-global-strategic-business-report-2026-capitalize-on-a-3-4-billion-market-by-203.md)
- [Microarray Analysis Market Size, Share, and Trends - Global Forecast 2026-2036 | Population Genotyping, Clinical Cytogenetics, and Asia-Pacific Growth Create a USD 2.58 Billion Opportunity](https://biotechnews.io/news/microarray-analysis-market-size-share-and-trends-global-forecast-2026-2036-population-geno.md)
- [Humanized Mouse and Rat Model - Global Strategic Business Report 2026: Capitalize on 9.7% CAGR to $231.6M by 2032 as Charles River, Biocytogen, Taconic and The Jackson Laboratory reshape drug R&D](https://biotechnews.io/news/humanized-mouse-and-rat-model-global-strategic-business-report-2026-capitalize-on-9-7-cagr.md)
